Poland· PL-100471118

Uplizna

A inebilizumab product containing inebilizumabum, registered in Poland by Amgen Europe B.V.. The same ATC class is registered in 3 of our 19 countries.

ATC L04AA47

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedUpliznaATCL04AA47REGISTER NO.PL-100471118PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Inebilizumab is registered in 3 of 19 countries.

Countries holding a registration under ATC L04AA47 (inebilizumab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 2 of them publish a price we can compare per daily dose

Inebilizumab · ATC L04AA47

3 / 19 countries

  • Ireland
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Inebilizumabum
Manufacturer
Amgen Europe B.V.
Country
Poland (PL)
ATC code
L04AA47
ATC class
Inebilizumab
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05397163001322
  • gtin
    08715131030216

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

51 interactions on record for inebilizumab.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Inebilizumab · interactions on record

51 records

  • 27 severe
  • 18 moderate
  • 6 minor

Most severe, free to view

  • CladribineL01BB04severe
  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Inebilizumab in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All inebilizumab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Uplizna
  • Norway · Uplizna

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2e5b318d-5a9e-46b1-aa23-709528344a38
GET /v1/drugs/2e5b318d-5a9e-46b1-aa23-709528344a38?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Koncentrat do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "100 mg",
  "packaging": "05397163001322 ¦ Rpz ¦ Skasowane ¦ EU/1/21/1602/001 ¦ 145750\n3 fiol. 10 ml\n08715131030216 ¦ Rpz ¦ EU/1/21/1602/001 ¦ 162425\n3 fiol. 10 ml",
  "substance": "Inebilizumabum 100 mg",
  "common_name": "Inebilizumabum",
  "pl_product_id": "100471118",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about inebilizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.